Bortezomib

Generic Name: Bortezomib

Brand Names: Velcade, Bortezomib Accord, Bortezomib Hospira, Bortezomib Fresenius Kabi, Bortezomib Sun

Drug Type: Small Molecule

Chemical Formula: C_₁₉H_₂₅BN_₄O_₄

CAS Number: 179324-69-7

Unique Ingredient Identifier: 69G8BD63PP

Background: Bortezomib is a dipeptide boronic acid derivative and proteasome inhibitor used to treat multiple myeloma and mantle cell lymphoma. The 26S proteasome is a protein complex that degrades ubiquitinated proteins in the ubiquitin-proteasome pathway: reversible inhibition of the 26S proteasome, leading to cell cycle arrest and apoptosis of cancer cells, is thought to be the main mechanism of action of bortezomib. However, multiple mechanisms may be involved in the anticancer activity of bortezomib.

Bortezomib was first synthesized in 1995. In May 2003, bortezomib became the first anticancer proteasome inhibitor that was approved by the FDA under the trade name VELCADE. Phase I, II, III, and IV clinical trials are undergoing to investigate the therapeutic efficacy of bortezomib in leukemia, myasthenia gravis, systemic lupus erythematosus, rheumatoid arthritis, and solid tumours.

Indication: Bortezomib is indicated for the treatment of adults with multiple myeloma or mantle cell lymphoma.

Associated Conditions: Mantle Cell Lymphoma (MCL), Multiple Myeloma (MM)

Associated Therapies: -

Clinical Trials

Vorinostat and Bortezomib in Treating Patients With Metastatic or Unresectable Solid Tumors

Phase 1

Completed

Conditions: Unspecified Adult Solid Tumor, Protocol Specific

Interventions: Drug: bortezomib
Drug: vorinostat

First Posted Date: 2005-09-28

Last Posted Date: 2014-02-24

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 66

Registration Number: NCT00227513

Locations: 🇺🇸
University of Wisconsin Hospital and Clinics, Madison, Wisconsin, United States

An Extension Study to Provide Bortezomib to Patients With Relapsed or Refractory Multiple Myeloma Who Previously Participated in a Bortezomib Phase I/II Study and Who May Benefit From Re-Treatment With or Continuation of Bortezomib Therapy

Phase 2

Completed

Conditions: Multiple Myeloma

First Posted Date: 2005-09-22

Last Posted Date: 2011-05-17

Lead Sponsor: Janssen Pharmaceutical K.K.

Target Recruit Count: 13

Registration Number: NCT00216697

Bortezomib and Antiviral Therapy Followed By Effusion Drainage, Bevacizumab, and Combination Chemotherapy in Treating Patients With Primary Effusion Lymphoma

Phase 2

Completed

Conditions: Lymphoma

First Posted Date: 2005-09-22

Last Posted Date: 2013-06-20

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 15

Registration Number: NCT00217503

Locations: 🇺🇸
Warren Grant Magnuson Clinical Center - NCI Clinical Trials Referral Office, Bethesda, Maryland, United States

Weekly Docetaxel and Bortezomib in the Treatment of Advanced Hormone-Refractory Prostate Cancer

Phase 2

Completed

Conditions: Prostate Cancer

First Posted Date: 2005-09-19

Last Posted Date: 2010-07-28

Lead Sponsor: SCRI Development Innovations, LLC

Target Recruit Count: 50

Registration Number: NCT00193232

Weekly Bortezomib (Velcade) in the Treatment of Patients With Refractory Multiple Myeloma

Phase 2

Completed

Conditions: Multiple Myeloma

First Posted Date: 2005-09-19

Last Posted Date: 2010-06-29

Lead Sponsor: SCRI Development Innovations, LLC

Target Recruit Count: 40

Registration Number: NCT00193557

Locations: 🇺🇸
Tennessee Oncology, PLLC, Nashville, Tennessee, United States
🇺🇸
Florida Cancer Specialists, Fort Myers, Florida, United States

Bortezomib in Treating Patients With Relapsed or Refractory Cutaneous T-Cell Lymphoma

Phase 2

Completed

Conditions: Lymphoma

Interventions: Drug: bortezomib

First Posted Date: 2005-09-16

Last Posted Date: 2020-08-03

Lead Sponsor: Jonsson Comprehensive Cancer Center

Target Recruit Count: 5

Registration Number: NCT00182637

Locations: 🇺🇸
Jonsson Comprehensive Cancer Center at UCLA, Los Angeles, California, United States

Bortezomib in Combination With CC-5013 in Patients With Relapsed/Refractory Multiple Myeloma

Phase 1

Completed

Conditions: Refractory Multiple Myeloma
Relapsed Multiple Myeloma
Multiple Myeloma

Interventions: Drug: Bortezomib
Drug: CC-5013

First Posted Date: 2005-09-12

Last Posted Date: 2016-01-25

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 58

Registration Number: NCT00153933

Locations: 🇺🇸
H. Lee Moffitt Cancer Center, Tampa, Florida, United States
🇺🇸
Winship Cancer Center, Atlanta, Georgia, United States
🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States

and more 3 locations

Bortezomib (Velcade) in Patients With Untreated Multiple Myeloma

Phase 2

Completed

Conditions: Multiple Myeloma

Interventions: Drug: bortezomib

First Posted Date: 2005-09-12

Last Posted Date: 2019-06-11

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 66

Registration Number: NCT00153920

Locations: 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
Emory Winship Cancer Institute, Atlanta, Georgia, United States

and more 3 locations